Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01728558
Other study ID # ANZIC-RC/YS003
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 2013
Est. completion date December 2018

Study information

Verified date April 2019
Source Australian and New Zealand Intensive Care Research Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Use of sedative drugs in intensive care is widespread. A cohort study conducted in Australia and New Zealand in 2010 revealed a high prevalence of deep sedation within the first 48 hours of mechanical ventilation which was independently linked to prolonged ventilation, hospital and 180 days mortality. Clinical practice is moving towards the use of lighter levels of sedation. Recent RCTs in Europe (JAMA 2012) and previous RCTs (JAMA 2009) supports growing evidence that dexmedetomidine facilitates rousable sedation, shortens ventilation time and attenuates delirium when compared to midazolam and propofol.

The investigators confirmed in a pilot study the feasibility, efficacy and safety of a process of care known as Early Goal Directed Sedation (EGDS) that delivers:

1. Early randomization after intubation or arrival in the ICU (intubated).

2. Early Adequate analgesia after randomization.

3. Goal directed sedation titrated to achieve light sedation.

4. Dexmedetomidine based algorithm as the primary sedative agent with avoidance of benzodiazepines.

The aim of this study is to assess the effectiveness of Early Goal Directed Sedation when compared to standard care sedation in critically ill patients.

The study hypothesis is that Early Goal-Directed Sedation (EGDS), compared to standard care sedation, reduces 90-day all-cause mortality in critically ill patients who require mechanical ventilation.


Description:

This is a large-scale study into the effectiveness of a novel approach for sedation in ventilated critically ill patients. The primary aim of this study is to determine whether Early Goal Directed Sedation therapy, compared to standard care sedation, reduces 90-day mortality in critically ill patients ventilated > 24 hrs.

The study will be a randomized, unblinded, controlled trial conducted in approximately 35-50 intensive care units (ICUs) and will recruit 4000 mechanically ventilated patients (life support) who are expected to remain on the ventilator > 24 hours AND require immediate ongoing sedative medication for comfort, safety, and to facilitate the delivery of life support measures, including mechanical ventilation.

Patients with primary brain injury or prolonged weakness are excluded. Participants will be randomized into one of 2 study groups. All patients will receive adequate analgesia at randomization at the discretion of treating clinician. All randomized patients will have Light sedation as the default target unless otherwise clinically indicated. The intervention group will receive EGDS with dexmedetomidine as the primary sedative agent to achieve light sedation, with the addition of propofol as required. The use of benzodiazepines in the intervention group is not allowed, with the exception of specific, defined circumstances.

The control group will have sedation according to usual practice as chosen by the treating clinician. The use of dexmedetomidine is not allowed, with the exception of specific, defined circumstances.

Deidentified data will be collected and will include; Baseline demographic information; Doses of all sedative, analgesic and other related medications; Pain, sedation and delirium scores and major treatments such as ventilation time, tracheostomy and dialysis. Patients surviving to hospital discharge will be contacted by phone to determine independent survival status at 90 days and again at 180 days plus Health Related Quality of Life and cognitive function assessment.


Recruitment information / eligibility

Status Completed
Enrollment 4000
Est. completion date December 2018
Est. primary completion date August 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient has been intubated and is receiving mechanical ventilation

- The treating clinician expects that the patient will remain intubated until the day after tomorrow (unlikely to be extubated the following day).

- The patient requires immediate ongoing sedative medication for comfort, safety, and to facilitate the delivery of life support measures.

Exclusion Criteria:

- Age less than 18 years

- Patient is pregnant and/or lactating

- Has been intubated (excluding time spent intubated within an operating theatre or transport) for greater than 12 hours in an intensive care unit.

- Proven or suspected acute primary brain lesion such as traumatic brain injury, intracranial haemorrhage, stroke, or hypoxic brain injury.

- Proven or suspected spinal cord injury or other pathology that may result in permanent or prolonged weakness.

- Admission as a consequence of a suspected or proven drug overdose or burns.

- Administration of ongoing neuromuscular blockade.

- A mean arterial blood (MAP) pressure that is less than 50 mmHg despite adequate resuscitation and vasopressor therapy at time of randomisation

- Heart rate less than 55 beats per minute unless the patient is being treated with a beta-blocker or a high grade atrio-ventricular block in the absence of a functioning pacemaker.

- Known sensitivity to any of the study medications or the constituents of propofol (egg, soya or peanut protein)

- Acute fulminant hepatic failure

- Patient has been receiving full time residential nursing care.

- Death is deemed to be imminent or inevitable during this admission and either the attending physician, patient or substitute decision maker is not committed to active treatment.

- Patient has an underlying disease that makes survival to 90 days unlikely

- Patient has been previously enrolled in the SPICE study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Early goal Directed Sedation

Standard care sedation


Locations

Country Name City State
Australia Albury Hospital Albury New South Wales
Australia Bendigo Hospital Bendigo Victoria
Australia Blacktown Hospital Blacktown New South Wales
Australia Sunshine Coast Hospital (Nambour Hospital) Buderim Queensland
Australia Dandenong Hospital Dandenong Victoria
Australia St Vincent's Hospital Sydney Darlinghurst New South Wales
Australia Lyell McEwan Hospital Elizabeth Vale South Australia
Australia Northern Hospital Epping Victoria
Australia Geelong Hospital Geelong Victoria
Australia Gosford Hospital Gosford New South Wales
Australia Austin Hospital Heidelberg Victoria
Australia Royal Brisbane and Women's hospital Herston Queensland
Australia Royal Hobart Hospital Hobart Tasmania
Australia Hornsby Ku-ring-gai Hospital Hornsby New South Wales
Australia Launceston General Hospital Launceston Tasmania
Australia Monash Medical Centre Melbourne Victoria
Australia Royal Melbourne Hospital Melbourne Victoria
Australia Nepean Hospital Penrith New South Wales
Australia St John Of God, Subiaco Perth Western Australia
Australia Redcliffe Hospital Redcliffe Queensland
Australia Central Gippsland Health Service Sale Victoria
Australia Gold Coast Hospital & Health Service Southport Queensland
Australia Royal North Shore Hospital St. Leonards New South Wales
Australia Prince of Wales Hospital Sydney New South Wales
Australia Royal Darwin Hospital Tiwi Northern Territory
Australia Toowoomba Hospital Toowoomba Queensland
Australia Knox Private Hospital Wantirna Victoria
Australia Westmead Hospital Westmead New South Wales
Australia Princess Alexandra Hospital Woolloongabba Queensland
Ireland St James's University Hospital Dublin Dublin 8
Ireland St Vincent's University Hospital Dublin Dublin 4
Italy Ospedale San Raffaele Milan
Malaysia Penang General Hospital George Town Pulau Pinang
Malaysia Raja Perempuan Zainab II Hospital Kota Bharu Kelantan
Malaysia Universiti Sains Malaysia Hospital Kota Bharu Kelantan
Malaysia Queen Elizabeth Hospital Kota Kinabalu Sabah
Malaysia Institut Jantung Negara Kuala Lumpur
Malaysia Kuala Lumpar General Hospital Kuala Lumpur
Malaysia University Malaya Medical Center Kuala Lumpur
Malaysia Sarawak General Hospital Kuching Sarawak
Malaysia Melaka General Hospital Melaka
New Zealand Christchurch Hospital Addington Christchurch
New Zealand Auckland City hospital Auckland
New Zealand Dunedin Hospital Dunedin
New Zealand Auckland City Hospital CVICU Grafton Auckland
New Zealand Wellington Hospital Newtown Wellington
New Zealand Middlemore Hospital Otahuhu Auckland
New Zealand Rotorua Hospital Rotorua
New Zealand North Shore Hospital Takapuna North Shore City
Saudi Arabia King Abdulaziz Medical City Riyadh
Saudi Arabia King Saud Medical City Riyadh
Saudi Arabia Prince Sultan Military Medical City Riyadh
Switzerland Inselspital University Hospital Bern Bern
United Kingdom Queen Elizabeth Hospital, Birmingham Birmingham
United Kingdom Royal Bournemouth Hospital Bournemouth
United Kingdom University Hospitals Bristol Bristol
United Kingdom Kings College Hospital Brixton London
United Kingdom University Hospital of Wales Cardiff
United Kingdom University Hospital of Coventry and Warwick Coventry
United Kingdom Derriford Hospital Crownhill Plymouth
United Kingdom Dorset County Hospital Dorchester
United Kingdom Royal Infirmary of Edinburgh Edinburgh
United Kingdom Western General Hospital Edinburgh
United Kingdom University Hospital of North Tees Hardwick Stockton-on-Tees
United Kingdom Freeman Hospital High Heaton Newcastle Upon Tyne
United Kingdom Queen Elizabeth Hospital King's Lynn King's Lynn Norfolk
United Kingdom Royal Liverpool University Hospital Liverpool
United Kingdom St George's Hospital London
United Kingdom St Thomas Hospital London
United Kingdom University College Hospital London
United Kingdom Altnagelvin Hospital Londonderry
United Kingdom Royal Victoria Infirmary Newcastle Upon Tyne
United Kingdom Princess Royal University Hospital Orpington
United Kingdom Royal Berkshire Hospital Reading

Sponsors (2)

Lead Sponsor Collaborator
Australian and New Zealand Intensive Care Research Centre National Health and Medical Research Council, Australia

Countries where clinical trial is conducted

Australia,  Ireland,  Italy,  Malaysia,  New Zealand,  Saudi Arabia,  Switzerland,  United Kingdom, 

References & Publications (1)

Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, McArthur C, Seppelt IM, Webb S, Weisbrodt L; Sedation Practice in Intensive Care Evaluation (SPICE) Study Investigators; ANZICS Clinical Trials Group. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med. 2012 Oct 15;186(8):724-31. doi: 10.1164/rccm.201203-0522OC. Epub 2012 Aug 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality Day 90 post randomisation
Secondary Ventilation free days at 28 days following randomisation
Secondary Proportion of RASS measurements in target range up to day 28
Secondary Incidence and duration of delirium measured by delirium free days up to 28 days
Secondary Length of ICU stay up to 180 days
Secondary Proportion of patients who receive a tracheostomy Proportion of patients who require: re-intubation, physical restraints,or unplanned extubation, up to day 28
Secondary Cumulative dose of midazolam, propofol, dexmedetomidine, fentanyl, and morphine up to 28 days
Secondary Duration of treatment with midazolam, propofol, dexmedetomidine, fentanyl, and morphine up to 28 days
Secondary Mortality at hospital discharge at hospital discharge up to 180 days
Secondary Length of hospital stay up to 180 days
Secondary Readmission to ICU at 90 days
Secondary EQ-5D questionnaire at 180 days
Secondary Cognitive function at 180 days
Secondary Mortality at ICU discharge up to 180 days
Secondary Full time institutional dependency at 180 days up to 180 days
Secondary Discharge destination up to 180 days